Organic Chemical – Page 34

Revival of Dormant Antipsychotic Class: LB Pharma’s Phase II Success with LB-102

11 months ago talkbio0Tagged Antipsychotic Agents, benzamide, LB-102, Pharma, Phase 2 Clinical Trials, Pounds, Schizophrenia

LB Pharma, LB-102, Antipsychotic drugs, Schizophrenia treatment, Phase II clinical trials, Benzamide antipsychotics

LB-102: Promising Phase 2 Results Revive Benzamide Antipsychotics for Schizophrenia Treatment in the US

11 months ago talkbio0Tagged Antipsychotic Agents, benzamide, dosing, LB-102, once-daily, PANSS, Phase 2 trial, safety profile, Schizophrenia, Score

LB-102, schizophrenia, benzamide antipsychotics, Phase 2 trial, PANSS scores, safety profile, once-daily dosing

LB Pharma’s Phase II Success Revitalizes Benzamide Antipsychotics for US Schizophrenia Treatment

11 months ago talkbio0Tagged Antipsychotic Agents, benzamide, Effectiveness, LB-102, Phase 2 Clinical Trials, Safety, Schizophrenia

LB-102, schizophrenia, benzamide antipsychotics, Phase II trial, efficacy, safety

Revance Therapeutics Faces Competing Buyout Offers: Teoxane SA Outbids Crown Laboratories

11 months ago talkbio0Tagged Biotechnology, Crown Laboratories, Industry, Revance, sulfanilamide, Teoxane

Revance Therapeutics, Teoxane SA, Crown Laboratories, buyout offers, merger agreement, biotechnology, skincare industry

Pfizer and PostEra Expand AI-Driven Drug Discovery Partnership to Include Antibody-Drug Conjugates (ADCs)

11 months ago talkbio0Tagged Antibody-Drug, Antibody-Drug Conjugates, Artificial Intelligence, Chemistry, Pharmaceutical, Drug Discovery, Immunostimulating conjugate (antigen), Laboratory, Pfizer, Pfizer/, PostEra, Proton Platform, Small Molecule

AI-driven drug discovery, Antibody-Drug Conjugates (ADCs), Pfizer, PostEra, AI Lab, Proton platform, small molecule therapeutics, medicinal chemistry.

J&J’s Rybrevant Combination Therapy Outperforms AstraZeneca’s Tagrisso in Lung Cancer Survival Trial

11 months ago talkbio0Tagged AstraZeneca, Combined Modality Therapy, J&J, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, Rybrevant, survival trial, Tagrisso

J&J, Rybrevant, AstraZeneca, Tagrisso, lung cancer, NSCLC, survival trial, combination therapy

Novartis Achieves Pivotal Trial Success for Intrathecal Zolgensma in Older SMA Patients After FDA Delay

12 months ago talkbio0Tagged Approved, intrathecal formulation, Novartis, older, Phase 3 trial, Spinal Muscular Atrophy, United States Food and Drug Administration, Zolgensma

Novartis, Zolgensma, Intrathecal formulation, Spinal muscular atrophy (SMA), FDA approval, Pivotal phase 3 trial, Older SMA patients

Cobenfy: A Breakthrough in Schizophrenia Treatment with a Novel Mechanism of Action

12 months ago talkbio0Tagged Antipsychotic Agents, Approved, Cobenfy, Muscarinic Acetylcholine Receptor, Myers, Schizophrenia, squibb, trospium chloride, United States Food and Drug Administration, xanomeline

Cobenfy, schizophrenia, muscarinic receptors, xanomeline, trospium chloride, Bristol Myers Squibb, Karuna Therapeutics, FDA approval, antipsychotic drugs.